In recent years, single-use technology has been migrating into many unit operations. With the commercial availability of such systems end users have a new option for process development and production that does not rely on operational complexities and utility requirements of conventional sterilize-in-place (SIP) or autoclavable systems. However, just as for cell culture processes, single-use technology may not apply to each and every fermentation or microbial process. It is the responsibility of practitioners to properly assess their own applications, select…
Author Archives: Kjell Eriksson
Optimization, Robustness, and Scale-Up of MAb Purification
The biopharmaceutical industry needs faster and more efficient development of new drugs and their market introduction as well as shorter process development times for both upstream and downstream operations. It has become more commonplace to use high-throughput development techniques to save time (1). Development is also sped up by applying platform technologies based on the unsurpassed selectivity of protein A resins (2,3,4,5,6), which is the foundation for downstream processing of monoclonal antibodies (MAbs). This is the second of two articles…